193 Results
Sort By:
Published on February 14, 2020
Researchers at Columbia University Department of Biomedical Engineering have engineered a novel probiotic strain of bacteria that can safely deliver immune checkpoint inhibiting nanobodies directly to tumors. When tested in cancer-bearing mice, a single dose of the bacteria continuously produced and released the anti-PD-L1 and anti-CTLA-4 nanobodies, triggering an immune…
Published on November 25, 2019
Since 2015, researchers with the Glioma Longitudinal Analysis (GLASS) Consortium have been studying the natural history of diffuse gliomas, and how their molecular anatomy changes over time. In the first analysis from the group, they discovered highly variable and patient-specific genomic alterations in patients with diffuse gliomas. They determined that…
Published on November 12, 2019
The FDA has granted marketing authorization to NantHealth’s Omics Core test, the company said today, clearing what it said is the nation’s first whole exome tumor-normal in vitro diagnostic (IVD) designed to measure overall tumor mutational burden (TMB) in cancer tissue. Omics Core is the first FDA authorized custom-targeted whole…
Published on November 6, 2019
Sponsored content brought to you by Checkpoint and Combination Therapy Overview Checkpoint immunotherapy development continues to grow at an incredible rate—as of 2018 there were more than 2250 clinical immunotherapy trials incorporating checkpoint therapy, with two of the three largest selling oncology drugs being checkpoint-based immunotherapies. As this field becomes…
Published on March 9, 2018
Prof. John Mattick, Ph.D., a global genomics pioneer who has served as executive director of Australia’s Garvan Institute of Medical Research since 2012, has been appointed the first CEO of Genomics England, the U.K. Department of Health entity created to run the 100,000 Genomes Project. Mattick will assume executive responsibilities…
Published on January 26, 2018
PlexBio said it plans to expand its 16-month-old collaboration with Denka by adding a new program in which the companies will codevelop a molecular diagnostic system designed to detect infectious disease. The companies envision a high-efficiency and high-accuracy system for rapid pathogenic microorganism identification that will initially include tests for…
Published on August 28, 2017
MedGenome said today it has completed a $30 million Series C financing, with the genomics research and diagnostics company directing proceeds toward its biomarker discovery programs and further development of its OncoPept™ suite of cancer immunotherapy biomarker solutions. The financing will allow genomic and biopharma researchers in the U.S. and…
Published on June 21, 2017
SerImmune, the developer of an immune mapping technology platform, has attracted a venture firm funded mostly by sequencing giant Illumina, as well as Merck & Co., among investors in an $8 million financing round announced yesterday. The lead investor was Illumina Ventures, an independently managed venture fund in a strategic…
Published on March 4, 2016
For all its genetic diversity, a tumor may yet display some common elements, antigens that reflect the tumor’s early mutational history. If these common elements could be identified, they could be used to target practically all of the tumor’s cells for destruction, and not just tumor cells that happen to…
Published on January 5, 2016
While the heterogeneity of influenza A infections has been understood for some time, the impact of minor strains on overall infection and transmission rates has been underappreciated. Now, a team of researchers led by scientists at New York University’s College of Global Public Health has discovered evidence strongly suggesting that…
Published on July 10, 2014
The polymerase chain reaction (PCR) has come a long way during the past three decades to become one of the fundamental platforms in life sciences sector. Normally, this is a sufficiently long period for a technology to mature and the market to move to decline phase. However, the PCR industry…
Published on April 15, 2014
Vural Özdemir, M.D., Ph.D., is editor-in-chief of OMICS: A Journal of Integrative Biology, published by Mary Ann Liebert, Inc. He is also an associate professor of human genetics at the council of higher education in Ankara, Turkey, and an independent scholar in science studies and advisor to the office of…